Loading...

Joseph Letourneau, MD

TitleClinical Fellow
InstitutionUniversity of California San Francisco
DepartmentOb/Gyn, Reproductive Sciences
Address550 16th. Street
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. Author Correction: A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. J Assist Reprod Genet. 2018 Feb; 35(2):309. PMID: 29178020.
      View in: PubMed
    2. Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. J Assist Reprod Genet. 2018 Feb; 35(2):297-307. PMID: 29086322.
      View in: PubMed
    3. Letourneau J, Sinha N, Wald K, Harris E, Quinn M, Imbar T, Mok-Lin E, Chien AJ, Rosen M. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017 Oct 01; 32(10):2123-2129. PMID: 28938748.
      View in: PubMed
    4. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 08; 165(1):161. PMID: 28660429.
      View in: PubMed
    5. Letourneau J, Cakmak H, Quinn M, Sinha N, I Cedars M, Rosen MP. Long-term hormonal contraceptive use is associated with a reversible suppression of antral follicle count and a break from hormonal contraception may improve oocyte yield. J Assist Reprod Genet. 2017 Sep; 34(9):1137-1144. PMID: 28669055.
      View in: PubMed
    6. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159. PMID: 28503722.
      View in: PubMed
    7. Quinn MM, Cakmak H, Letourneau J, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017 03 01; 32(3):568-574. PMID: 28122888.
      View in: PubMed
    8. Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, Rosen MP. Regret around fertility choices is decreased with pre-treatment counseling in gynecologic cancer patients. J Cancer Surviv. 2017 Feb; 11(1):58-63. PMID: 27480882.
      View in: PubMed
    9. Chan JL, Letourneau J, Salem W, Cil AP, Chan SW, Chen LM, Rosen MP. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery. Gynecol Oncol. 2015 Oct; 139(1):141-7. PMID: 26232519.
      View in: PubMed
    10. Letourneau J, Chan J, Salem W, Chan SW, Shah M, Ebbel E, McCulloch C, Chen LM, Cedars M, Rosen M. Fertility Sparing Surgery for Localized Ovarian Cancers Maintains an Ability to Conceive, but is Associated With Diminished Reproductive Potential. J Surg Oncol. 2015 Jul; 112(1):26-30. PMID: 26193338.
      View in: PubMed
    11. Quinn MM, Letourneau J, Rosen MP. Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk. Contraception. 2014 May; 89(5):466-71. PMID: 24576795.
      View in: PubMed
    12. Letourneau J, Chan SW, Rosen MP. Accelerating ovarian age: cancer treatment in the premenopausal woman. Semin Reprod Med. 2013 Nov; 31(6):462-8. PMID: 24101227.
      View in: PubMed
    13. Niemasik EE, Letourneau J, Dohan D, Katz A, Melisko M, Rugo H, Rosen M. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors. J Cancer Surviv. 2012 Sep; 6(3):324-32. PMID: 22752834.
      View in: PubMed
    14. Letourneau J, Smith JF, Ebbel EE, Craig A, Katz PP, Cedars MI, Rosen MP. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer. 2012 Sep 15; 118(18):4579-88. PMID: 22451228; PMCID: PMC3387319.
    15. Letourneau J, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012 Mar 15; 118(6):1710-7. PMID: 21887678; PMCID: PMC3235264.
    16. Letourneau J, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012 Apr 01; 118(7):1933-9. PMID: 21850728; PMCID: PMC3220922.
    17. Letourneau J, Melisko ME, Cedars MI, Rosen MP. A changing perspective: improving access to fertility preservation. Nat Rev Clin Oncol. 2011 01; 8(1):56-60. PMID: 20736926; PMCID: PMC3226819.